Clinical Trial Update: The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk

View source ↗

Summary

A completed clinical trial found that the association between serum amyloid A (SAA) and apolipoprotein B influences cardiovascular risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Snippet

Sponsor: Lisa Tannock | Conditions: Cardiovascular Disease | Status: COMPLETED